ACM
EDIT icon

AlphaCrest Capital Management’s Editas Medicine EDIT Stock Holding History

AlphaCrest Capital Management’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-51,696
Closed -$633K – 351
2022
Q3 		$633K Buy
51,696
+37,595
+267% +$586K 0.04% 871
2022
Q2 		$167K Sell
14,101
-11,052
-44% -$148K 0.01% 1216
2022
Q1 		$478K Buy
25,153
+2,760
+12% +$51.3K 0.03% 917
2021
Q4 		$595K Buy
22,393
+11,057
+98% +$381K 0.02% 1035
2021
Q3 		$466K Buy
+11,336
New +$621K 0.02% 948
2021
Q2 		– Sell
-8,100
Closed -$340K – 1249
2021
Q1 		$340K Buy
8,100
+3,200
+65% +$182K 0.02% 967
2020
Q4 		$344K Sell
4,900
-3,800
-44% -$156K 0.03% 848
2020
Q3 		$244K Buy
+8,700
New +$283K 0.03% 966
2019
Q4 		– Sell
-23,900
Closed -$543K – 1272
2019
Q3 		$543K Sell
23,900
-30,200
-56% -$748K 0.03% 868
2019
Q2 		$1.34M Buy
54,100
+35,100
+185% +$838K 0.12% 269
2019
Q1 		$465K Buy
+19,000
New +$430K 0.07% 488

Other funds holding EDIT

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

AlphaCrest Capital Management's EDIT Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Editas Medicine (EDIT) in Q4 2022, closing a stake of 51,696 shares — an estimated $633K sold.

AlphaCrest Capital Management first reported a position in EDIT in Q1 2019 and held it in 11 quarters. The position peaked at $1.34M in Q2 2019. 251 funds tracked by Wall St. Rank hold EDIT as of Q4 2022.

  • AlphaCrest Capital Management reported no remaining Editas Medicine position as of Q4 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 51,696 Editas Medicine shares in Q4 2022, an estimated $633K.
  • AlphaCrest Capital Management first reported a position in Editas Medicine in Q1 2019 and held it in 11 quarters.
  • AlphaCrest Capital Management's Editas Medicine position peaked at $1.34M in Q2 2019.
  • 251 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.